Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Buy at JonesTrading

JonesTrading upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a research report report published on Wednesday,Benzinga reports. The firm currently has $29.00 target price on the stock.

Several other analysts have also weighed in on the company. Barclays cut their price objective on Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, November 7th. Wolfe Research reissued a “peer perform” rating on shares of Intellia Therapeutics in a report on Wednesday, November 12th. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a research report on Monday. Wells Fargo & Company boosted their target price on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Eleven equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.59.

Intellia Therapeutics Trading Up 1.6%

Shares of NASDAQ:NTLA opened at $13.82 on Wednesday. The company has a 50 day moving average of $12.17 and a 200-day moving average of $13.10. The firm has a market cap of $1.63 billion, a P/E ratio of -3.61 and a beta of 2.10. Intellia Therapeutics has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. The business had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The business’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.27) earnings per share. Equities research analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP James Basta sold 10,397 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Schroder Investment Management Group boosted its position in Intellia Therapeutics by 1,593.4% during the 2nd quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock worth $3,812,000 after acquiring an additional 382,425 shares during the period. Marex Group plc purchased a new stake in shares of Intellia Therapeutics in the second quarter worth approximately $5,849,000. JPMorgan Chase & Co. boosted its holdings in shares of Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock worth $8,822,000 after purchasing an additional 396,858 shares during the period. AXQ Capital LP acquired a new stake in shares of Intellia Therapeutics during the second quarter worth approximately $285,000. Finally, SG Americas Securities LLC grew its position in Intellia Therapeutics by 239.7% during the third quarter. SG Americas Securities LLC now owns 131,070 shares of the company’s stock valued at $2,264,000 after purchasing an additional 92,485 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.